Indapta Therapeutics
A biotechnology company focused on developing a natural killer cell therapy with potent ADCC activity to treat cancer.
A biotechnology company focused on developing a natural killer cell therapy with potent ADCC activity to treat cancer.
Indapta Therapeutics is a biotechnology company founded in 2017, headquartered in the United States, and positioned at the forefront of developing a natural killer cell therapy with potent ADCC activity to combat cancer. Their allogeneic g-NK cells, known for their highly potent ADCC activity, are suitable for combination with IgG1 monoclonal antibodies, ADCs, or innate immune cell engager molecules. Their recent investment of $4.50M in the form of a grant, received on May 21, 2024, came from the Cancer Prevention and Research Institute of Texas.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $4.50M | 1 | Cancer Prevention and Research Institute of Texas | 21 May 2024 |
| Series A | $50.00M | 5 |
|
10 Feb 2022 |
| Venture Round | Unknown | 1 |
|
08 Aug 2021 |
| Pre Seed Round | Unknown | 1 |
|
19 Dec 2019 |
| Pre Seed Round | Unknown | 1 |
|
09 May 2019 |
No recent news or press coverage available for Indapta Therapeutics.
온코인사이트---OncoInsight-Co.,-Ltd.-logo.jpg){kind=logo}
We care about your data, and we'd love to use cookies make your experience better.
